Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference
September 19 2022 - 3:15PM
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX:
TH) (NASDAQ: THTX), a biopharmaceutical company focused on the
development and commercialization of innovative therapies, today
announced that Paul Levesque, President and Chief Executive
Officer, will participate on the “Novel Targets in Oncology: Risk
vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc
Conference to be held at the New York Palace Hotel, on Wednesday,
September 28, 2022, at 9:00 a.m. ET, in New York City. The
presentation is available only to attendees of the conference:
https://www.cantor.com/cantor-oncology-hemonc-conference/
Along with Mr. Levesque, Chief Financial
Officer, Mr. Philippe Dubuc and Chief Medical Officer, Dr.
Christian Marsolais will participate in a variety of meetings
during the day of the conference.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies addressing unmet medical
needs. Further information about Theratechnologies is available on
the Company's website at www.theratech.com, on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov.
Investor Contact:Elif
McDonaldSenior Director, Investor
Relationsir@theratech.com1-438-315-8563
Media Contact:Julie SchneidermanSenior
Director, Communications & Corporate
Affairscommunications@theratech.com1-514-336-7800
Theratechnologies (TSX:TH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theratechnologies (TSX:TH)
Historical Stock Chart
From Apr 2023 to Apr 2024